FitzSimons David, Hendrickx Greet, Hallauer Johannes, Larson Heidi, Lavanchy Daniel, Lodewyckx Ina, Shouval Daniel, Ward John, Van Damme Pierre
305 Route des Alpes, 01280 Prévessin, France.
2Viral Hepatitis Prevention Board (VHPB), Centre for the Evaluation of Vaccination, Vaccine & Infectious Diseases Institute, University of Antwerp, Universiteitsplein 1, B-2610 Antwerpen, Belgium.
Hepatol Med Policy. 2016 Dec 16;1:16. doi: 10.1186/s41124-016-0022-8. eCollection 2016.
Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with hepatitis B or C virus have not been screened yet and are unaware of their infections; and most countries, especially developing countries, do not have a national plan to prevent and control viral hepatitis. The advent of effective new treatments for hepatitis C has been an agent of change, allowing consideration of the feasibility of eliminating that disease and accelerating the control of viral hepatitis generally. These facts inspired the Viral Hepatitis Prevention Board (VHPB) to organize a meeting in London (8-9 June 2015) on innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries. The main focus of the meeting was to provide an overview of current health systems controlling viral hepatitis in low- and middle-income countries (LMICs); to identify ways to increase political commitment and financial sustainability of viral hepatitis prevention and control programmes in such countries; to identify potential funders and explore new funding mechanisms; to discuss lessons learnt about funding other disease programmes; to investigate how to convince and motivate decision-makers to fund viral hepatitis programmes in LMICs; to provide options for improving access to affordable screening and treatment of viral hepatitis in LMICs; and to list the commitments required for funding by donors, including governments, bilateral and multilateral organizations, non-traditional donors, development banks, foundations, and commercial financial institutions. To improve viral hepatitis prevention and treatment in LMICs participating hepatitis and financing experts identified the most urgent needs. Data on burden of disease must be improved. Comprehensive hepatitis policies and strategies should be drafted and implemented, and existing strategies and policies improved to increase access to treatment and prevention. Strong political will and leadership should be generated, potential partners identified and partnerships created. Potential funders and funding mechanisms have to be researched. The outcome of this meeting was integrated in a VHPB project to investigate creative financing solutions to expand access to and provision of screening and other preventive services, treatment and care of hepatitis B and C in LMICs. The report is available on www.vhpb.org.
乙型肝炎是可预防的,丙型肝炎是可治疗的,即便治疗成本仍然高昂;大多数感染乙型或丙型肝炎病毒的人尚未接受筛查,也不知道自己已被感染;而且大多数国家,尤其是发展中国家,没有预防和控制病毒性肝炎的国家计划。丙型肝炎有效新疗法的出现带来了变革,使得人们能够考虑消除该疾病的可行性,并总体上加速病毒性肝炎的防控。这些事实促使病毒性肝炎预防委员会(VHPB)于2015年6月8日至9日在伦敦组织了一次会议,探讨为低收入和中等收入国家的病毒性肝炎预防和治疗筹集资金的创新来源。会议的主要重点是概述低收入和中等收入国家目前控制病毒性肝炎的卫生系统;确定增强这些国家病毒性肝炎预防和控制计划的政治承诺和财政可持续性的方法;确定潜在的资助者并探索新的筹资机制;讨论从其他疾病计划筹资中吸取的经验教训;研究如何说服并激励决策者为低收入和中等收入国家的病毒性肝炎计划提供资金;提供改善低收入和中等收入国家获得负担得起的病毒性肝炎筛查和治疗的选择;列出捐助者(包括政府、双边和多边组织、非传统捐助者、开发银行、基金会和商业金融机构)提供资金所需的承诺。为了改善低收入和中等收入国家的病毒性肝炎预防和治疗,与会的肝炎和筹资专家确定了最紧迫的需求。必须改进疾病负担数据。应起草并实施全面的肝炎政策和战略,并改进现有战略和政策,以增加获得治疗和预防的机会。应产生强大的政治意愿和领导力,确定潜在伙伴并建立伙伴关系。必须研究潜在的资助者和筹资机制。本次会议的成果被纳入VHPB的一个项目,以研究创新融资解决方案,扩大低收入和中等收入国家获得乙型和丙型肝炎筛查及其他预防服务、治疗和护理的机会并提供这些服务。该报告可在www.vhpb.org上获取。